LIQUIDIA TECHNOLOGIES INC

NASDAQ: LQDA (Liquidia Corporation)

Kemas kini terakhir: 5 hari lalu, 7:06PM

61.86

-0.17 (-0.27%)

Penutupan Terdahulu 62.03
Buka 61.50
Jumlah Dagangan 1,242,517
Purata Dagangan (3B) 1,370,163
Modal Pasaran 5,501,091,840
Harga / Pendapatan (P/E TTM) 363.88
Harga / Pendapatan (P/E Ke hadapan) 29.41
Harga / Jualan (P/S) 19.06
Harga / Buku (P/B) 49.94
Julat 52 Minggu
11.85 (-80%) — 63.46 (2%)
Tarikh Pendapatan 12 Aug 2026
Margin Operasi (TTM) -1,135.42%
EPS Cair (TTM) -1.71
Pertumbuhan Hasil Suku Tahunan (YOY) 5.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 297.04%
Nisbah Semasa (MRQ) 2.93
Aliran Tunai Operasi (OCF TTM) -99.23 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -64.38 M
Pulangan Atas Aset (ROA TTM) -37.66%
Pulangan Atas Ekuiti (ROE TTM) -203.98%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Menaik
Drug Manufacturers - Specialty & Generic (Global) Bercampur Menaik
Stok Liquidia Corporation Menaik Menaik

AISkor Stockmoo

-1.7
Konsensus Penganalisis -3.0
Aktiviti Orang Dalam -4.0
Volatiliti Harga -3.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal 4.0
Purata -1.70

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LQDA 6 B - 363.88 49.94
ALKS 7 B - 46.88 3.50
LNTH 7 B - 24.54 5.21
INDV 4 B - 18.98 145.25
PAHC 1 B 1.56% 13.21 3.57
EVO 1 B - - 1.33

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 13.64%
% Dimiliki oleh Institusi 65.04%

Pemilikan

Nama Tarikh Syer Dipegang
Findell Capital Management Llc 31 Mar 2026 3,502,112
Julat 52 Minggu
11.85 (-80%) — 63.46 (2%)
Julat Harga Sasaran
44.00 (-28%) — 55.00 (-11%)
Tinggi 55.00 (HC Wainwright & Co., -11.09%) Beli
Median 52.00 (-15.94%)
Rendah 44.00 (Wells Fargo, -28.87%) Beli
Purata 50.75 (-17.96%)
Jumlah 4 Beli
Harga Purata @ Panggilan 35.28
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 06 Mar 2026 55.00 (-11.09%) Beli 36.03
Wells Fargo 06 Mar 2026 44.00 (-28.87%) Beli 36.03
BTIG 05 Mar 2026 50.00 (-19.17%) Beli 34.52
Needham 05 Mar 2026 54.00 (-12.71%) Beli 34.52

Tiada data dalam julat masa ini.

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda